Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy

Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue i...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Silvia, Tempora, Patrizia, Melaiu, Ombretta, Lucarini, Valeria, Cifaldi, Loredana, Locatelli, Franco, Fruci, Doriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352877/
https://www.ncbi.nlm.nih.gov/pubmed/35936007
http://dx.doi.org/10.3389/fimmu.2022.948297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352877/
https://www.ncbi.nlm.nih.gov/pubmed/35936007
http://dx.doi.org/10.3389/fimmu.2022.948297

Ejemplares similares